| Year |
Citation |
Score |
| 2022 |
Brierley SM, Greenwood-Van Meerveld B, Sarnelli G, Sharkey KA, Storr M, Tack J. Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome. Nature Reviews. Gastroenterology & Hepatology. PMID 36168049 DOI: 10.1038/s41575-022-00682-y |
0.436 |
|
| 2020 |
Szymaszkiewicz A, Włodarczyk J, Wasilewski A, Di Marzo V, Storr M, Fichna J, Zielińska M. Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 32002574 DOI: 10.1007/S00210-020-01829-X |
0.329 |
|
| 2020 |
Kienzl M, Storr M, Schicho R. Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. Clinical and Translational Gastroenterology. PMID 31899693 DOI: 10.14309/Ctg.0000000000000120 |
0.33 |
|
| 2019 |
Fabisiak A, Włodarczyk M, Fabisiak N, Storr M, Fichna J. Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis. Journal of Gastrointestinal and Liver Diseases : Jgld. 28: 473-481. PMID 31826058 DOI: 10.15403/Jgld-265 |
0.356 |
|
| 2019 |
Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J. Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43]. European Journal of Pharmacology. 172656. PMID 31519354 DOI: 10.1016/J.Ejphar.2019.172656 |
0.337 |
|
| 2019 |
Szymaszkiewicz A, Malkiewicz A, Storr M, Fichna J, Zielinska M. The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome. Journal of Physiology and Pharmacology : An Official Journal of the Polish Physiological Society. 70. PMID 31019119 DOI: 10.26402/Jpp.2019.1.01 |
0.332 |
|
| 2018 |
Szymaszkiewicz A, Storr M, Fichna J, Zielinska M. Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. e13526. PMID 30549162 DOI: 10.1111/Nmo.13526 |
0.336 |
|
| 2018 |
Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J. The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. European Journal of Pharmacology. PMID 30121173 DOI: 10.1016/J.Ejphar.2018.08.016 |
0.357 |
|
| 2018 |
Szymaszkiewicz A, Zielinska M, Li K, Ramanathan M, Alam S, Hou DR, Fichna J, Storr M. Novel derivatives of 1,2,3-triazole, cannabinoid-1 receptor ligands modulate gastrointestinal motility in mice. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 29404698 DOI: 10.1007/S00210-018-1465-9 |
0.308 |
|
| 2017 |
Binienda A, Storr M, Fichna J, Salaga M. Efficacy and safety of serotonin receptor ligands in the treatment of irritable bowel syndrome: a review. Current Drug Targets. PMID 29284389 DOI: 10.2174/1389450119666171227225408 |
0.355 |
|
| 2017 |
Salaga M, Zatorski H, Zielińska M, Mosinska P, Timmermans JP, Kordek R, Storr M, Fichna J. Highly selective CB receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice. Naunyn-Schmiedeberg's Archives of Pharmacology. 390: 1015-1027. PMID 28710683 DOI: 10.1007/S00210-017-1402-3 |
0.34 |
|
| 2017 |
Bashashati M, Fichna J, Piscitelli F, Capasso R, Izzo AA, Sibaev A, Timmermans JP, Cenac N, Vergnolle N, Di Marzo V, Storr M. Targeting fatty acid amide hydrolase and transient receptor potential vanilloid-1 simultaneously to modulate colonic motility and visceral sensation in the mouse: A pharmacological intervention with N-arachidonoyl-serotonin (AA-5-HT). Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 29. PMID 28695708 DOI: 10.1111/Nmo.13148 |
0.324 |
|
| 2017 |
Fabisiak A, Włodarczyk J, Fabisiak N, Storr M, Fichna J. Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal. Journal of Neurogastroenterology and Motility. PMID 28551943 DOI: 10.5056/Jnm16203 |
0.342 |
|
| 2017 |
Wasilewski A, Lewandowska U, Mosinska P, Watala C, Storr M, Fichna J, Venkatesan T. Cannabinoid Receptor Type 1 and mu-Opioid Receptor Polymorphisms Are Associated With Cyclic Vomiting Syndrome. The American Journal of Gastroenterology. PMID 28349993 DOI: 10.1038/Ajg.2017.73 |
0.305 |
|
| 2017 |
Hasenoehrl C, Storr M, Schicho R. Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Expert Review of Gastroenterology & Hepatology. 11: 329-337. PMID 28276820 DOI: 10.1080/17474124.2017.1292851 |
0.341 |
|
| 2017 |
Mosińska P, Zatorski H, Storr M, Fichna J. Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor Agonists. Journal of Neurogastroenterology and Motility. PMID 28238253 DOI: 10.5056/Jnm16183 |
0.333 |
|
| 2017 |
Zielińska M, Fichna J, Bashashati M, Habibi S, Sibaev A, Timmermans JP, Storr M. G protein-coupled estrogen receptor and estrogen receptor ligands regulate colonic motility and visceral pain. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 29. PMID 28191706 DOI: 10.1111/Nmo.13025 |
0.336 |
|
| 2017 |
Taschler U, Hasenoehrl C, Storr M, Schicho R. Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance. Handbook of Experimental Pharmacology. PMID 28161834 DOI: 10.1007/164_2016_105 |
0.381 |
|
| 2016 |
Hasenoehrl C, Taschler U, Storr M, Schicho R. The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 28: 1765-1780. PMID 27561826 DOI: 10.1111/Nmo.12931 |
0.36 |
|
| 2016 |
Jarmuż A, Banaszek M, Leń K, Storr M, Zielińska M, Fichna J. The role of MOP and DOP receptors in treatment of diarrhea-predominant irritable bowel syndrome. Mini Reviews in Medicinal Chemistry. PMID 27494159 DOI: 10.2174/1389557516666160804165318 |
0.346 |
|
| 2016 |
Krohn RM, Parsons SA, Fichna J, Patel KD, Yates RM, Sharkey KA, Storr MA. Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment. Journal of Inflammation (London, England). 13: 21. PMID 27418880 DOI: 10.1186/S12950-016-0129-0 |
0.439 |
|
| 2016 |
Sobolewska-Włodarczyk A, Włodarczyk M, Storr M, Fichna J. Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Therapeutics and Clinical Risk Management. 12: 771-5. PMID 27257381 DOI: 10.2147/Tcrm.S83722 |
0.331 |
|
| 2016 |
Zielińska M, Jarmuż A, Sałaga M, Kordek R, Laudon M, Storr M, Fichna J. Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice. Naunyn-Schmiedeberg's Archives of Pharmacology. PMID 26899972 DOI: 10.1007/S00210-016-1214-X |
0.318 |
|
| 2016 |
Salaga M, Storr M, Martemyanov KA, Fichna J. RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. PMID 26817719 DOI: 10.1002/Bies.201500118 |
0.304 |
|
| 2015 |
Abalo R, Chen C, Vera G, Fichna J, Thakur GA, López-Pérez AE, Makriyannis A, Martín-Fontelles MI, Storr M. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. PMID 26387676 DOI: 10.1111/Nmo.12668 |
0.329 |
|
| 2015 |
Fichna J, Poole DP, Veldhuis N, MacEachern SJ, Saur D, Zakrzewski PK, Cygankiewicz AI, Mokrowiecka A, Małecka-Panas E, Krajewska WM, Liedtke W, Steinhoff MS, Timmermans JP, Bunnett NW, Sharkey KA, ... Storr MA, et al. Transient receptor potential vanilloid 4 inhibits mouse colonic motility by activating NO-dependent enteric neurotransmission. Journal of Molecular Medicine (Berlin, Germany). PMID 26330151 DOI: 10.1007/s00109-015-1336-5 |
0.485 |
|
| 2015 |
Zoller V, Laguna AL, Prazeres Da Costa O, Buch T, Göke B, Storr M. [Fecal microbiota transfer (FMT) in a patient with refractory irritable bowel syndrome]. Deutsche Medizinische Wochenschrift (1946). 140: 1232-6. PMID 26261935 DOI: 10.1055/S-0041-103798 |
0.31 |
|
| 2015 |
Sibaev A, Fichna J, Saur D, Yuece B, Timmermans JP, Storr M. Nociceptin effect on intestinal motility depends on opioid-receptor like-1 receptors and nitric oxide synthase co-localization. World Journal of Gastrointestinal Pharmacology and Therapeutics. 6: 73-83. PMID 26261735 DOI: 10.4292/Wjgpt.V6.I3.73 |
0.325 |
|
| 2015 |
Stančić A, Jandl K, Hasenöhrl C, Reichmann F, Marsche G, Schuligoi R, Heinemann A, Storr M, Schicho R. The GPR55 antagonist CID16020046 protects against intestinal inflammation. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 27: 1432-45. PMID 26227635 DOI: 10.1111/Nmo.12639 |
0.359 |
|
| 2015 |
Taschler U, Eichmann TO, Radner FP, Grabner GF, Wolinski H, Storr M, Lass A, Schicho R, Zimmermann R. Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity. British Journal of Pharmacology. 172: 4419-29. PMID 26075589 DOI: 10.1111/Bph.13224 |
0.376 |
|
| 2015 |
Jarmuż A, Zielińska M, Storr M, Fichna J. Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 27: 1057-68. PMID 25930667 DOI: 10.1111/Nmo.12574 |
0.348 |
|
| 2015 |
Wasilewski A, Zieli?ska M, Storr M, Fichna J. Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 21: 1674-82. PMID 25822014 DOI: 10.1097/Mib.0000000000000364 |
0.325 |
|
| 2015 |
Bashashati M, Nasser Y, Keenan CM, Ho W, Piscitelli F, Nalli M, Mackie K, Storr MA, Di Marzo V, Sharkey KA. Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. British Journal of Pharmacology. 172: 3099-111. PMID 25684407 DOI: 10.1111/Bph.13114 |
0.406 |
|
| 2015 |
Keenan CM, Storr MA, Thakur GA, Wood JT, Wager-Miller J, Straiker A, Eno MR, Nikas SP, Bashashati M, Hu H, Mackie K, Makriyannis A, Sharkey KA. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. British Journal of Pharmacology. 172: 2406-18. PMID 25572435 DOI: 10.1111/Bph.13069 |
0.442 |
|
| 2015 |
Wasilewski A, Storr M, Zieli?ska M, Fichna J. Role of G protein-coupled orphan receptors in intestinal inflammation: novel targets in inflammatory bowel diseases. Inflammatory Bowel Diseases. 21: 666-73. PMID 25461621 DOI: 10.1097/Mib.0000000000000258 |
0.35 |
|
| 2014 |
Fichna J, Bawa M, Thakur GA, Tichkule R, Makriyannis A, McCafferty DM, Sharkey KA, Storr M. Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors. Plos One. 9: e109115. PMID 25275313 DOI: 10.1371/Journal.Pone.0109115 |
0.558 |
|
| 2014 |
Chen C, Yu Z, Li Y, Fichna J, Storr M. Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications. The American Journal of Chinese Medicine. 42: 1053-70. PMID 25183302 DOI: 10.1142/S0192415X14500669 |
0.314 |
|
| 2014 |
Fichna J, Sobczak M, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, Cenac N, Sa?aga M, Timmermans JP, Vergnolle N, Ma?ecka-Panas E, Krajewska WM, Storr M. Activation of the endogenous nociceptin system by selective nociceptin receptor agonist SCH 221510 produces antitransit and antinociceptive effect: a novel strategy for treatment of diarrhea-predominant IBS. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 26: 1539-50. PMID 25041572 DOI: 10.1111/Nmo.12390 |
0.361 |
|
| 2014 |
Sibaev A, Yuece B, Allescher HD, Saur D, Storr M, Kurjak M. The endocannabinoid anandamide regulates the peristaltic reflex by reducing neuro-neuronal and neuro-muscular neurotransmission in ascending myenteric reflex pathways in rats. Pharmacological Reports : Pr. 66: 256-63. PMID 24911079 DOI: 10.1016/J.Pharep.2013.09.008 |
0.327 |
|
| 2014 |
Sa?aga M, Mokrowiecka A, Zakrzewski PK, Cygankiewicz A, Leishman E, Sobczak M, Zatorski H, Ma?ecka-Panas E, Kordek R, Storr M, Krajewska WM, Bradshaw HB, Fichna J. Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). Journal of Crohn's & Colitis. 8: 998-1009. PMID 24530133 DOI: 10.1016/J.Crohns.2014.01.025 |
0.325 |
|
| 2014 |
Schicho R, Storr M. Cannabis finds its way into treatment of Crohn's disease. Pharmacology. 93: 1-3. PMID 24356243 DOI: 10.1159/000356512 |
0.329 |
|
| 2014 |
Sobczak M, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, Sałaga M, Storr M, Kordek R, Małecka-Panas E, Krajewska WM, Fichna J. Anti-inflammatory and antinociceptive action of an orally available nociceptin receptor agonist SCH 221510 in a mouse model of inflammatory bowel diseases. The Journal of Pharmacology and Experimental Therapeutics. 348: 401-9. PMID 24345466 DOI: 10.1124/Jpet.113.209825 |
0.382 |
|
| 2014 |
Füllhase C, Campeau L, Sibaev A, Storr M, Hennenberg M, Gratzke C, Stief C, Hedlund P, Andersson KE. Bladder function in a cannabinoid receptor type 1 knockout mouse. Bju International. 113: 144-51. PMID 24053792 DOI: 10.1111/Bju.12350 |
0.303 |
|
| 2014 |
Botteselle L, Zhao X, Göke B, Sibaev A, Storr M. Su2040 Interaction Between GPR119 and CB1 Receptors in the Inhibition of Contractile Activity in Mouse and Human Gut Gastroenterology. 146: S-530. DOI: 10.1016/S0016-5085(14)61918-1 |
0.302 |
|
| 2013 |
Li YY, Cao MH, Goetz B, Chen CQ, Feng YJ, Chen CJ, Kasparek MS, Sibaev A, Storr M, Kreis ME. The dual effect of cannabinoid receptor-1 deficiency on the murine postoperative ileus. Plos One. 8: e67427. PMID 23844009 DOI: 10.1371/Journal.Pone.0067427 |
0.35 |
|
| 2013 |
Sobczak M, Sałaga M, Storr M, Fichna J. Nociceptin / orphanin FQ (NOP) receptors as novel potential target in the treatment of gastrointestinal diseases. Current Drug Targets. 14: 1203-9. PMID 23773151 DOI: 10.2174/13894501113149990174 |
0.372 |
|
| 2013 |
Fichna J, Sibaev A, Sałaga M, Sobczak M, Storr M. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 25: e550-9. PMID 23692073 DOI: 10.1111/Nmo.12158 |
0.361 |
|
| 2013 |
Li K, Fichna J, Schicho R, Saur D, Bashashati M, Mackie K, Li Y, Zimmer A, Göke B, Sharkey KA, Storr M. A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. Neuropharmacology. 71: 255-63. PMID 23603203 DOI: 10.1016/J.Neuropharm.2013.03.029 |
0.549 |
|
| 2013 |
Li YY, Yuece B, Cao HM, Lin HX, Lv S, Chen JC, Ochs S, Sibaev A, Deindl E, Schaefer C, Storr M. Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis. Laboratory Investigation; a Journal of Technical Methods and Pathology. 93: 322-33. PMID 23381627 DOI: 10.1038/Labinvest.2012.177 |
0.31 |
|
| 2013 |
Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders. Wiener Medizinische Wochenschrift (1946). 163: 65-72. PMID 23263639 DOI: 10.1007/S10354-012-0169-X |
0.3 |
|
| 2013 |
Michler T, Storr M, Kramer J, Ochs S, Malo A, Reu S, Göke B, Schäfer C. Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms. American Journal of Physiology. Gastrointestinal and Liver Physiology. 304: G181-92. PMID 23139224 DOI: 10.1152/Ajpgi.00133.2012 |
0.32 |
|
| 2013 |
Fichna J, Habibi S, Bashashati M, Storr M. Mo2098 A Novel Function for Estrogen Receptor GPR30: Control of Gastrointestinal Motility and Visceral Sensation Gastroenterology. 144: S-741-S-742. DOI: 10.1016/S0016-5085(13)62750-X |
0.319 |
|
| 2012 |
Schicho R, Storr M. A potential role for GPR55 in gastrointestinal functions. Current Opinion in Pharmacology. 12: 653-8. PMID 23063456 DOI: 10.1016/J.Coph.2012.09.009 |
0.362 |
|
| 2012 |
Bashashati M, Rezaei N, Bashashati H, Shafieyoun A, Daryani NE, Sharkey KA, Storr M. Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 24: 1102-e566. PMID 22897390 DOI: 10.1111/J.1365-2982.2012.01990.X |
0.465 |
|
| 2012 |
Schicho R, Storr M. Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology. 89: 149-55. PMID 22414698 DOI: 10.1159/000336871 |
0.323 |
|
| 2012 |
Bassaganya-Riera J, Viladomiu M, Pedragosa M, De Simone C, Carbo A, Shaykhutdinov R, Jobin C, Arthur JC, Corl BA, Vogel H, Storr M, Hontecillas R. Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis. Plos One. 7: e31238. PMID 22363592 DOI: 10.1371/Journal.Pone.0031238 |
0.322 |
|
| 2012 |
Hons IM, Storr MA, Mackie K, Lutz B, Pittman QJ, Mawe GM, Sharkey KA. Plasticity of mouse enteric synapses mediated through endocannabinoid and purinergic signaling. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 24: e113-24. PMID 22235973 DOI: 10.1111/J.1365-2982.2011.01860.X |
0.421 |
|
| 2012 |
Bashashati M, Rezaei N, Andrews CN, Chen CQ, Daryani NE, Sharkey KA, Storr MA. Cytokines and irritable bowel syndrome: where do we stand? Cytokine. 57: 201-9. PMID 22178716 DOI: 10.1016/J.Cyto.2011.11.019 |
0.441 |
|
| 2012 |
Bashashati M, Storr MA, Nikas SP, Wood JT, Godlewski G, Liu J, Ho W, Keenan CM, Zhang H, Alapafuja SO, Cravatt BF, Lutz B, Mackie K, Kunos G, Patel KD, et al. Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. British Journal of Pharmacology. 165: 1556-71. PMID 21883147 DOI: 10.1111/J.1476-5381.2011.01644.X |
0.543 |
|
| 2012 |
Bashashati M, Rezaei N, Bashashati H, Shafieyoun A, Daryani NE, Sharkey KA, Storr M. Tu1427 Interleukin-10 and TGF-1 Anti-Inflammatory Cytokine Gene Polymorphisms are Involved in the Pathophysiology of Irritable Bowel Syndrome: A Meta-Analysis Gastroenterology. 142: S-830. DOI: 10.1016/S0016-5085(12)63221-1 |
0.473 |
|
| 2011 |
Chen CQ, Fichna J, Bashashati M, Li YY, Storr M. Distribution, function and physiological role of melatonin in the lower gut. World Journal of Gastroenterology : Wjg. 17: 3888-98. PMID 22025877 DOI: 10.3748/Wjg.V17.I34.3888 |
0.373 |
|
| 2011 |
Schicho R, Storr M. Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 25: 377-83. PMID 21876860 DOI: 10.1155/2011/953975 |
0.331 |
|
| 2011 |
Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu HM, Zimmer A, Lutz B, Mackie K, Bradshaw HB, McCafferty DM, Sharkey KA, Storr M. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflammatory Bowel Diseases. 17: 1651-64. PMID 21744421 DOI: 10.1002/Ibd.21538 |
0.528 |
|
| 2011 |
Lin XH, Yuece B, Li YY, Feng YJ, Feng JY, Yu LY, Li K, Li YN, Storr M. A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 23: 862-e342. PMID 21726355 DOI: 10.1111/J.1365-2982.2011.01742.X |
0.367 |
|
| 2010 |
Schicho R, Storr M. Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies. Expert Review of Clinical Pharmacology. 3: 193-207. PMID 22111567 DOI: 10.1586/Ecp.09.62 |
0.327 |
|
| 2010 |
Gach K, do-Rego JC, Fichna J, Storr M, Delbro D, Toth G, Janecka A. Synthesis and biological evaluation of novel peripherally active morphiceptin analogs. Peptides. 31: 1617-24. PMID 20434497 DOI: 10.1016/J.Peptides.2010.04.018 |
0.318 |
|
| 2010 |
Storr MA, Bashashati M, Hirota C, Vemuri VK, Keenan CM, Duncan M, Lutz B, Mackie K, Makriyannis A, Macnaughton WK, Sharkey KA. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 22: 787-96, e223. PMID 20180825 DOI: 10.1111/J.1365-2982.2010.01478.X |
0.496 |
|
| 2010 |
Yüce B, Kemmer M, Qian G, Müller M, Sibaev A, Li Y, Kreis ME, Storr M. Cannabinoid 1 receptors modulate intestinal sensory and motor function in rat. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 22: 672-e205. PMID 20158615 DOI: 10.1111/J.1365-2982.2010.01473.X |
0.308 |
|
| 2010 |
Li YY, Li YN, Ni JB, Chen CJ, Lv S, Chai SY, Wu RH, Yüce B, Storr M. Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 22: 350-e88. PMID 19840270 DOI: 10.1111/J.1365-2982.2009.01419.X |
0.345 |
|
| 2009 |
Fichna J, Schicho R, Janecka A, Zjawiony JK, Storr M. Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. Drug News & Perspectives. 22: 383-92. PMID 19890495 DOI: 10.1358/Dnp.2009.22.7.1400219 |
0.32 |
|
| 2009 |
Fichna J, Schicho R, Andrews CN, Bashashati M, Klompus M, McKay DM, Sharkey KA, Zjawiony JK, Janecka A, Storr MA. Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 21: 1326-e128. PMID 19650775 DOI: 10.1111/J.1365-2982.2009.01369.X |
0.483 |
|
| 2009 |
Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflammatory Bowel Diseases. 15: 1678-85. PMID 19408320 DOI: 10.1002/Ibd.20960 |
0.497 |
|
| 2009 |
Sibaev A, Yüce B, Kemmer M, Van Nassauw L, Broedl U, Allescher HD, Göke B, Timmermans JP, Storr M. Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon. American Journal of Physiology. Gastrointestinal and Liver Physiology. 296: G119-28. PMID 19033531 DOI: 10.1152/Ajpgi.90274.2008 |
0.321 |
|
| 2009 |
Storr M, Bashashati M, Vemuri K, Alapafuja S, Ho W, Keenan CM, Kunos G, Makriyannis A, Davison JS, Sharkey KA. W1697 Regional Specificity of Fatty Acid Amide Hydrolase (FAAH) Inhibition On Contractility in the Mouse Intestine: Endotoxin Upregulation of Faah Sensitivity in the Ileum Gastroenterology. 136: A-719. DOI: 10.1016/S0016-5085(09)63320-5 |
0.473 |
|
| 2008 |
Storr MA, Yüce B, Andrews CN, Sharkey KA. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 20: 857-68. PMID 18710476 DOI: 10.1111/J.1365-2982.2008.01175.X |
0.49 |
|
| 2008 |
Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yüce B, Sibaev A, Massa F, Buckley NE, Lutz B, Göke B, Brand S, Patel KD, Sharkey KA. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. Journal of Molecular Medicine (Berlin, Germany). 86: 925-36. PMID 18493729 DOI: 10.1007/S00109-008-0359-6 |
0.477 |
|
| 2008 |
Hons IM, Keenan CM, Storr M, Lutz B, Sharkey KA. M1239 Alterations in Synaptic Transmission in the Enteric Nervous System and Correlation to Motility Defects in CB1 Receptor-Deficient Mice Gastroenterology. 134: A-368. DOI: 10.1016/S0016-5085(08)61715-1 |
0.49 |
|
| 2008 |
Storr M, Keenan CM, Zhang H, Patel KD, Sharkey KA. S1737 Drugs Inhibiting Endocannabinoid Degradation Protect Against Experimental Colitis in Mice Gastroenterology. 134: A-260. DOI: 10.1016/S0016-5085(08)61208-1 |
0.466 |
|
| 2007 |
Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Current Opinion in Pharmacology. 7: 575-82. PMID 17904903 DOI: 10.1016/j.coph.2007.08.008 |
0.471 |
|
| 2007 |
Yuece B, Sibaev A, Broedl UC, Marsicano G, Göke B, Lutz B, Allescher HD, Storr M. Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 19: 744-53. PMID 17727394 DOI: 10.1111/J.1365-2982.2007.00975.X |
0.373 |
|
| 2007 |
Yüce B, Sibaev A, Haaken A, Saur D, Allescher HD, Göke B, Timmermans JP, Storr M. ORL-1 receptor mediates the action of nociceptin on ascending myenteric reflex pathways in rats. Gastroenterology. 133: 574-86. PMID 17681177 DOI: 10.1053/J.Gastro.2007.05.016 |
0.348 |
|
| 2007 |
Storr M. TRPV1 in colitis: is it a good or a bad receptor?--a viewpoint. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 19: 625-9. PMID 17539893 DOI: 10.1111/J.1365-2982.2007.00946.X |
0.344 |
|
| 2006 |
Sibaev A, Massa F, Yüce B, Marsicano G, Lehr HA, Lutz B, Göke B, Allescher HD, Storr M. CB1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice. Journal of Molecular Medicine (Berlin, Germany). 84: 513-20. PMID 16501934 DOI: 10.1007/S00109-006-0040-X |
0.328 |
|
| 2006 |
Storr M, Yüce B, Göke B. [Perspectives of cannabinoids in gastroenterology]. Zeitschrift Fã¼R Gastroenterologie. 44: 185-91. PMID 16456761 DOI: 10.1055/S-2005-858931 |
0.303 |
|
| 2006 |
Massa F, Sibaev A, Marsicano G, Blaudzun H, Storr M, Lutz B. Vanilloid receptor (TRPV1)-deficient mice show increased susceptibility to dinitrobenzene sulfonic acid induced colitis. Journal of Molecular Medicine (Berlin, Germany). 84: 142-6. PMID 16389550 DOI: 10.1007/S00109-005-0016-2 |
0.381 |
|
| 2005 |
Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. Journal of Molecular Medicine (Berlin, Germany). 83: 944-54. PMID 16133420 DOI: 10.1007/S00109-005-0698-5 |
0.385 |
|
| 2005 |
Sibaev A, Massa F, Yüce B, Marsicano G, Lehr H, Lutz B, Göke B, Allescher H, Storr M. CB1 and TRPV1 receptors mediate protective effects on electrophysiological properties during colonic inflammation Zeitschrift FüR Gastroenterologie. 43. DOI: 10.1055/S-2005-919919 |
0.349 |
|
| 2004 |
Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, Lutz B. The endogenous cannabinoid system protects against colonic inflammation. The Journal of Clinical Investigation. 113: 1202-9. PMID 15085199 DOI: 10.1172/Jci19465 |
0.385 |
|
| 2004 |
Storr M, Sibaev A, Marsicano G, Lutz B, Schusdziarra V, Timmermans JP, Allescher HD. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. American Journal of Physiology. Gastrointestinal and Liver Physiology. 286: G110-7. PMID 12893627 DOI: 10.1152/Ajpgi.00148.2003 |
0.333 |
|
| 2003 |
Storr M, Sibaev A, Marsicano G, Lutz B, Allescher H. Excitatory cholinergic and inhibitory non-adrenergic, non-cholinergic neurotransmission in murine colon is modulated by the CB1 cannabinoid receptor. Intracellular recording in wild-type and CB1-deficient mice Gastroenterology. 124: A116-A117. DOI: 10.1016/S0016-5085(03)80573-5 |
0.319 |
|
| 2002 |
Storr M, Thammer J, Dunkel R, Schusdziarra V, Allescher HD. Modulatory effect of adenosine receptors on the ascending and descending neural reflex responses of rat ileum. Bmc Neuroscience. 3: 21. PMID 12495441 DOI: 10.1186/1471-2202-3-21 |
0.338 |
|
| 2002 |
Storr M, Koppitz P, Sibaev A, Saur D, Kurjak M, Franck H, Schusdziarra V, Allescher HD. Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro. Journal of Pineal Research. 33: 101-8. PMID 12153444 DOI: 10.1034/J.1600-079X.2002.02909.X |
0.317 |
|
| 2002 |
Storr M, Gaffal E, Schusdziarra V, Allescher HD. Endomorphins 1 and 2 reduce relaxant non-adrenergic, non-cholinergic neurotransmission in rat gastric fundus. Life Sciences. 71: 383-9. PMID 12044838 DOI: 10.1016/S0024-3205(02)01681-8 |
0.331 |
|
| 2002 |
Storr M, Hahn A, Gaffal E, Saur D, Allescher HD. Effects of endomorphin-1 and -2 on mu-opioid receptors in myenteric neurons and in the peristaltic reflex in rat small intestine. Clinical and Experimental Pharmacology & Physiology. 29: 428-34. PMID 12010188 DOI: 10.1046/J.1440-1681.2002.03681.X |
0.311 |
|
| 2002 |
Storr M, Gaffal E, Saur D, Schusdziarra V, Allescher HD. Effect of cannabinoids on neural transmission in rat gastric fundus. Canadian Journal of Physiology and Pharmacology. 80: 67-76. PMID 11911227 DOI: 10.1139/Y02-005 |
0.321 |
|
| 2000 |
Storr M, Meining A, Allescher HD. Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. Digestive Diseases (Basel, Switzerland). 18: 93-102. PMID 11060472 DOI: 10.1159/000016970 |
0.31 |
|
| 2000 |
Allescher HD, Storr M, Brechmann C, Hahn A, Schusdziarra V. Modulatory effect of endogenous and exogenous opioids on the excitatory reflex pathway of the rat ileum. Neuropeptides. 34: 62-8. PMID 10688971 DOI: 10.1054/Npep.1999.0789 |
0.3 |
|
| Show low-probability matches. |